OBJECTIVE: In vitro treatment of Nf2-deficient cells with epidermal growth factor receptor (EGFR) inhibitors can reduce cellular proliferation. We sought to determine the activity of erlotinib for progressive vestibular schwannoma (VS) associated with neurofibromatosis 2 (NF2). STUDY DESIGN: Retrospective case review. SETTING: Tertiary referral center. PATIENTS: Eleven NF2 patients with progressive VS who were poor candidates for standard therapy. INTERVENTION: Erlotinib 150 mg daily. MAIN OUTCOME MEASURES: A radiographic response was defined as >or= 20% decrease in tumor volume compared with baseline. A hearing response was defined as a statistically significant increase in word recognition score (WRS) compared with baseline; a minor hearing response was defined as a 10 dB improvement in pure-tone average with stable WRS. RESULTS: : Before treatment, the median and mean annual volumetric growth rate for 11 index VS were 26% and 46%, respectively. Among 10 evaluable patients, the median time-to-tumor progression was 9.2 months. Three patients with stable disease experienced maximum tumor shrinkage of 4%, 13%, and 14%. Nine patients underwent audiologic evaluations. One experienced a transient hearing response, 2 experienced minor hearing responses, 3 remained stable, and 2 developed progressive hearing loss. The median time-to-progressive hearing loss was 9.2 months and to either tumor growth or progressive hearing loss was 7.1 months. Adverse treatment effects included mild-to-moderate rash, diarrhea, and hair thinning, with 2 episodes of grade 3 toxicity. CONCLUSION: Erlotinib treatment was not associated with radiographic or hearing responses in NF2 patients with progressive VS. Because a subset of patients experienced prolonged stable disease, time-to-progression may be more appropriate than radiographic or hearing response for anti-EGFR agents in NF2-associated VS.
OBJECTIVE: In vitro treatment of Nf2-deficient cells with epidermal growth factor receptor (EGFR) inhibitors can reduce cellular proliferation. We sought to determine the activity of erlotinib for progressive vestibular schwannoma (VS) associated with neurofibromatosis 2 (NF2). STUDY DESIGN: Retrospective case review. SETTING: Tertiary referral center. PATIENTS: Eleven NF2patients with progressive VS who were poor candidates for standard therapy. INTERVENTION: Erlotinib 150 mg daily. MAIN OUTCOME MEASURES: A radiographic response was defined as >or= 20% decrease in tumor volume compared with baseline. A hearing response was defined as a statistically significant increase in word recognition score (WRS) compared with baseline; a minor hearing response was defined as a 10 dB improvement in pure-tone average with stable WRS. RESULTS: : Before treatment, the median and mean annual volumetric growth rate for 11 index VS were 26% and 46%, respectively. Among 10 evaluable patients, the median time-to-tumor progression was 9.2 months. Three patients with stable disease experienced maximum tumor shrinkage of 4%, 13%, and 14%. Nine patients underwent audiologic evaluations. One experienced a transient hearing response, 2 experienced minor hearing responses, 3 remained stable, and 2 developed progressive hearing loss. The median time-to-progressive hearing loss was 9.2 months and to either tumor growth or progressive hearing loss was 7.1 months. Adverse treatment effects included mild-to-moderate rash, diarrhea, and hair thinning, with 2 episodes of grade 3 toxicity. CONCLUSION:Erlotinib treatment was not associated with radiographic or hearing responses in NF2patients with progressive VS. Because a subset of patients experienced prolonged stable disease, time-to-progression may be more appropriate than radiographic or hearing response for anti-EGFR agents in NF2-associated VS.
Authors: D E Brackmann; J N Fayad; W H Slattery; R A Friedman; J D Day; W E Hitselberger; R M Owens Journal: Neurosurgery Date: 2001-08 Impact factor: 4.654
Authors: Hon Kit Wong; Johanna Lahdenranta; Walid S Kamoun; Annie W Chan; Andrea I McClatchey; Scott R Plotkin; Rakesh K Jain; Emmanuelle di Tomaso Journal: Cancer Res Date: 2010-04-20 Impact factor: 12.701
Authors: Jaishri O Blakeley; D Gareth Evans; John Adler; Derald Brackmann; Ruihong Chen; Rosalie E Ferner; C Oliver Hanemann; Gordon Harris; Susan M Huson; Abraham Jacob; Michel Kalamarides; Matthias A Karajannis; Bruce R Korf; Victor-Felix Mautner; Andrea I McClatchey; Harry Miao; Scott R Plotkin; William Slattery; Anat O Stemmer-Rachamimov; D Bradley Welling; Patrick Y Wen; Brigitte Widemann; Kim Hunter-Schaedle; Marco Giovannini Journal: Am J Med Genet A Date: 2011-12-02 Impact factor: 2.802
Authors: Vivek Subbiah; John Slopis; David S Hong; Leena M Ketonen; Jackson Hamilton; Ian E McCutcheon; Razelle Kurzrock Journal: J Clin Oncol Date: 2011-12-27 Impact factor: 44.544
Authors: Kent A Robertson; Grzegorz Nalepa; Feng-Chun Yang; Daniel C Bowers; Chang Y Ho; Gary D Hutchins; James M Croop; Terry A Vik; Scott C Denne; Luis F Parada; Cynthia M Hingtgen; Laurence E Walsh; Menggang Yu; Kamnesh R Pradhan; Mary K Edwards-Brown; Mervyn D Cohen; James W Fletcher; Jeffrey B Travers; Karl W Staser; Melissa W Lee; Marcie R Sherman; Cynthia J Davis; Lucy C Miller; David A Ingram; D Wade Clapp Journal: Lancet Oncol Date: 2012-10-23 Impact factor: 41.316
Authors: Janet L Oblinger; Sarah S Burns; Elena M Akhmametyeva; Jie Huang; Li Pan; Yulin Ren; Rulong Shen; Beth Miles-Markley; Aaron C Moberly; A Douglas Kinghorn; D Bradley Welling; Long-Sheng Chang Journal: Neuro Oncol Date: 2016-03-06 Impact factor: 12.300
Authors: Matthias A Karajannis; Geneviève Legault; Mari Hagiwara; Marc S Ballas; Krysten Brown; Annette O Nusbaum; Tsivia Hochman; Judith D Goldberg; Kevin M Koch; John G Golfinos; J Thomas Roland; Jeffrey C Allen Journal: Neuro Oncol Date: 2012-07-27 Impact factor: 12.300